For tumors, or -more often- their metastases, that are refractive to these treatments, Adoptive Cell Therapy (ACT) using administration of cytotoxic CD8+ T cells, engineered to improve their specificity for tumor antigens, is producing increasingly promising results [1]. The gene discussed is CD8A; the disease is neoplasm.